公开(公告)号：US20210106528A1

公开(公告)日：2021-04-15

申请号：US17125291

申请日：2020-12-17

Applicant: FUJIFILM Corporation

Inventor： Takashi KOMORI ,  Tadaaki IOROI ,  Takeshi MATSUMOTO ,  Yasuyuki IZUMI

IPC: A61K9/127 ,  A61K31/7068 ,  A61P35/00

Abstract: An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

公开(公告)号：US20230285295A1

公开(公告)日：2023-09-14

申请号：US18199903

申请日：2023-05-19

Applicant: FUJIFILM Corporation

Inventor： Takashi KOMORI ,  Tadaaki IOROI ,  Takeshi MATSUMOTO ,  Yasuyuki IZUMI

IPC: A61K9/127 ,  A61P35/00 ,  A61K31/7068

CPC classification number: A61K9/127 ,  A61P35/00 ,  A61K31/7068 ,  A61K45/06

Abstract: An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.